Preliminary Phase 1 Data From Ongoing Firstin-Human Phase 1/2 TRESR Study of RP-3500

Virtual Investor Update October 8, 2021



Brief introduction	Lloyd M. Segal & Maria Koehler, MD, PhD	President & CEO, Repare Therapeutics EVP & CMO, Repare Therapeutics	
Summary of AACR-NCI-EOTRC data and select case studies	Timothy Yap, MBBS, PhD, FRCP	Medical Director, Institute for Applied Cancer Science, Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center	
RP-3500 next steps	Maria Koehler, MD, PhD Timothy Yap, MBBS, PhD, FRCP	EVP & CMO, Repare Therapeutics MD Anderson Cancer Center	
Concluding remarks	Lloyd M. Segal & Maria Koehler, MD, PhD	President & CEO, Repare Therapeutics EVP & CMO, Repare Therapeutics	

REPARE THERAPEUTICS

Q&A



Lloyd M. Segal President & CEO

Joining for Q&A



Mike Zinda, PhD Chief Scientific Officer



Maria Koehler, MD, PhD Chief Medical Officer



Steve Forte Chief Financial Officer



Disclaimer

Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," "plans," "potential," "projects," "would" and "future" or similar expressions are intended to identify forward-looking statements. Each of these forward-looking statements involves substantial risks and uncertainties that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding the initiation, timing, progress and results of our current and future preclinical studies and clinical trials; the expected timing of program updates and data disclosures; the timing of filing INDs and other regulatory documents; the timing and likelihood of seeking regulatory approval for our product candidates; the competitive landscape for our product candidates; our ability to identify and develop additional product candidates using our SNIPRx platform; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.


These forward-looking statements reflect our current beliefs and expectations. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and unexpected litigation or other disputes. These and other risks are described more fully in our filings with the Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of our Quarterly Report on Form 10-Q filed with the SEC on August 12, 2021, and other documents we subsequently filed with or furnished to the SEC. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Except as required by law, we assume no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Solely for convenience, the trademarks and trade names in this presentation may be referred to without the [®] and [™] symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto.



Leading clinical-stage precision oncology company focused on synthetic lethality





Powerful SL-based approach and proprietary platform provides differentiated patient selection insights



Cash, restricted cash and marketable securities of \$301 million as of June 30, 2021



Expert participant: Timothy Yap, MBBS, PhD, FRCP



Medical Oncologist and Physician-Scientist at the University of Texas, MD Anderson Cancer Center

- Associate Professor, Department for Investigational Cancer Therapeutics
- Medical Director of the Institute for Applied Cancer Science
- Associate Director of Translational Research in the Institute for Personalized Cancer Therapy
- Primary research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers
- Main interests include the targeting of the DNA damage response with novel therapeutics, such as ATR and PARP inhibitors, as well as the development of novel immuno-therapeutics
- BSc degree in Immunology and Infectious Diseases and MD from Imperial College London, UK



Robust pipeline of SL-based precision oncology therapeutics

		SL	Pair]					
		Tumor lesion	Drug target	Discovery	IND-Enabling	Phase 1/2	Registration- directed	Anticipated milestones	Rights
Clinical	ATR inhibitor RP-3500	ATM + 16 STEP ² lesions	ATR	MonoRx data		■ Q3 22 PARP combo	REPARE THERAPEUTICS		
Clin	PKMYT1 inhibitor RP-6306	CCNE1, FBXW7 + others	PKMYT1					H2 22 early Phase 1 readout	REPARE THERAPEUTICS
Preclinical	Polθ inhibitor	BRCA1/2+ others	ΡοΙθ					IND-enabling studies in H1 22	REPARE THERAPEUTICS
very	8 additional		SL targets						REPARE THERAPEUTICS
Discovery	platform							REPARE THERAPEUTICS (^{III}) Bristol Myers Squibb [®]	



Expanding RP-3500 patient opportunity with STEP² selection tools*

Top 10 tumor types with highest prevalence of ATM deficiency

Top 10 tumor types with highest prevalence of ATM deficiency or STEP² genomic alterations




Beyond ATM, 16 of 19 additional, mutually exclusive genomic alterations identified as SL with RP-3500 are eligible for recruitment into the ongoing trial

- Represents expanded, clinically relevant populations with unmet medical needs
- Average prevalence of ~2% (ATM) to ~10% (STEP² genes) across multiple tumors



RP-3500 clinical progress to-date

Global multicenter study designed for patients with recurrent tumors with ATM loss or loss of any of the additional 16 STEP² genes





Summary of AACR-NCI-EORTC data and select case studies





AACR-NCI-EORTC Virtual International Conference on **MOLECULAR TARGETS AND CANCER THERAPEUTICS** October 7-10, 2021



FINDING CURES TOGETHER





First-in-Human biomarker-driven Phase I TRESR trial of ATR inhibitor RP-3500 in patients with advanced solid tumors harboring synthetic lethal genomic alterations

Timothy A. Yap¹, Elizabeth Lee², David Spigel³, Elisa Fontana⁴, Martin Hojgaard⁵, Stephanie Lheureux⁶, Niharika Mettu⁷, Louise Carter⁸, Ruth Plummer⁹, Victoria Rimkunas¹⁰, Ian M. Silverman¹⁰, Adrian J. Fretland¹⁰, Danielle Ulanet¹⁰, Peter Manley¹⁰, Ezra Rosen¹¹

¹University of Texas MD Anderson Cancer Center, Houston, TX; ²Dana-Farber Cancer Institute, Boston, MA; ³Sarah Cannon Research Institute, Nashville, TN; ⁴Sarah Cannon Research Institute, London, UK; ⁵Copenhagen University Hospital, Herlev, Denmark; ⁶Princess Margaret Cancer Centre, Toronto, Canada; ⁷Duke University Medical Center, Durham, NC; ⁸The Christie NHS Foundation Trust, Manchester, UK; ⁹Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; ¹⁰Repare Therapeutics, Cambridge, MA; ¹¹Memorial Sloan Kettering Cancer Center, New York, NY




I have the following financial relationships to disclose:

- Employee of: University of Texas MD Anderson Cancer Center, where I am Medical Director of the Institute for Applied Cancer Science, which has a commercial interest in DDR and other inhibitors.
- Grant/Research support (to Institution) from: Repare, AstraZeneca, Artios, Bayer, Beigene, BioNTech, BMS, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, Artios, GlaxoSmithKline, Genentech, Haihe, ImmuneSensor, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tesaro and Vivace.
- Consultant for: Repare, AstraZeneca, Almac, Aduro, Artios, Athena, Atrin, Axiom, Bayer, Bristol Myers Squibb, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, GLG, Guidepoint, Ignyta, I-Mab, ImmuneSensor, Jansen, Merck, Pfizer, Roche, Schrodinger, Seattle Genetics, Varian, Zai Labs and ZielBio
- Stockholder in: Seagen
- I will discuss the following off label use and/or investigational use in my presentation: RP-3500




RP-3500: a potential best-in-class, highly selective inhibitor of ATR kinase



ATR inhibition is synthetically lethal with genomic alterations affecting DNA damage response

- ATR is a key mediator of cellular DNA damage response (DDR) and is activated in response to DNA replication stress
- A genome-wide CRISPR-based screening platform identified multiple synthetic lethal genomic alterations that predict for sensitivity to RP-3500 (STEP^{2*} genes)
- ATM, ATRIP, BRCA1/2, CHEK2, CDK12, CHTF8, FZR1, MRE11, NBN, PALB2, RAD17, RAD50, RAD51B/C/D, REV3L, RNASEH2A/B, SETD2

*STEP² = SNIPRX** targeted expansion of patient populations **SNIPRx = SyNthetic lethal Interactions for Precision Rx



RP-3500 is a potent and highly selective inhibitor of ATR

- Low nanomolar potency in biochemical (1.0 nM) and cell-based assays (0.33 nM)
- >2,000-fold selectivity over ATM, DNA-PK and PI3Ka
- Single agent activity in tumor models of different histologies and DDR defects

Roulston et al., ENA 2021, #PO54



Phase 1/2 TRESR (Treatment Enabled by SNIPRx) study

> NCT04497116 (accruing)

Inclusion Criteria

- Patients ≥18yo with solid tumors resistant, refractory, and/or intolerant to standard therapy
- Tumors with centrally reviewed* deleterious STEP² alterations
- ECOG PS 0 or 1
- Hgb ≥9.5g/dL, Platelets ≥140K/uL, ANC ≥1.7K/uL

Module 1: single agent RP-3500

Primary endpoints:

- Safety and tolerability
- Recommended Phase 2 dose (RP2D), schedule

Other endpoints

- Pharmacokinetics
- Pharmacodynamics in paired tumor biopsies
- Preliminary antitumor activity
- Kinetics of circulating tumor DNA (ctDNA)

Presentation of **<u>early data</u>** from this ongoing study:

- TRESR initiated in July 2020
- Data cut-off date: August 15, 2021
- 101 patients included in this early dataset



Phase 1/2 TRESR: patient characteristics

All patients		N = 101
	Male Female	42 59
Median age, years	(range)	63 (33-77)
	≥65 yrs	46
ECOG status		
	0 1	48 53
Lines of prior thera	ру	
	1-3 4 or more Pending	51 45 5
Prior Platinum		62
Prior PARP inhibito	r	28
Prior PD-1/L1 inhib	20	

Tumor types				
Ovaria	n 19			
Prostat	e 18			
Breas	st 13			
Pancrea	s 8			
Sarcom	a 8			
Other	* 35			

Most common genotypes

ATM	37
BRCA1	31
BRCA2	13
CDK12	7
Other STEP2**	23

*other tumor types:

- CRC
- Bile Duct
- GI
- Endometrial
- Lung
- Ampullary
- Appendix
- HNSCC
- Melanoma
- Mesothelioma
- Skin
- **STEP² genotypes:
- CHEK2
- NBN
- PALB2
- RAD51C/B
- RNASEH2
- SETD2
- FZR1



RP-3500 MTD/RP2D established at 160mg QD, 3d on/4d off schedule


Comprehensive assessment for RP-3500 MTD/RP2D

Single agent RP-3500 tested at multiple doses and schedules

- Adaptive BOIN design and sufficient cohort sizes to ensure confidence in MTD/RP2D decision
- Once daily (QD) and twice daily (BID)
- 5d on/2d off and 3d on/4d off; continuously and 2w on/1w off

DLTs: anemia, thrombocytopenia

MTD/RP2D of RP-3500: 160mg QD, 3d on/4d off





RP-3500 treatment emergent adverse events

All grades, occurring in ≥10% of patients

		5/2 Schedule (N=25)		3/4 Schedule (N=76)		All Patients (N=101)			
Preferred term	All Grade n (%)	Grade 3 n (%)	Grade 4 n (%)	All Grade n (%)	Grade 3 n (%)	Grade 4 n (%)	All Grade n (%)	Grade 3 n (%)	Grade 4 n (%)
Any TEAE	25 (100)	15 (60)	2 (8)	58 (76.3)	19 (25.0)	1 (1.3)	83 (82.2)	34 (33.7)	3 (3.0)*
Anemia	19 (76)	11 (44)	0	40 (52.2)	11 (14.5)	0	59 (58.4)	22 (21.8)	0
Fatigue	9 (36)	1 (4)	0	19 (25.0)	2 (2.6)	0	28 (27.7)	3 (3.0)	0
Decreased appetite	6 (24)	0	0	17 (22.4)	0	0	23 (22.8)	0	0
Nausea	6 (24)	0	0	16 (21.1)	1 (1.3)	0	22 (21.8)	1 (1.0)	0
Neutrophil count decreased	5 (20)	2 (8)	0	14 (18.4)	4 (5.3)	0	19 (18.8)	6 (5.9)	0
Platelet count decreased	7 (28)	2 (8)	1 (4)	12 (15.8)	3 (3.9)	1 (1.3)	19 (18.8)	5 (5.0)	2 (2.0)*
Diarrhea	3 (12)	0	0	14 (18.4)	0	0	17 (16.8)	0	0
Abdominal pain	3 (12)	0	0	8 (10.5)	1 (1.3)	0	11 (10.9)	1 (1.0)	0

MTD/RP2D established at 160mg QD, 3d on/4d off



Manageable impact of on-target anemia


- Anemia is the most common cause of dose interruptions, modifications
- At the preferred 3/4 schedule, dose interruptions, reductions and transfusions were infrequent
- No discontinuations related to RP-3500 emergent adverse events

IIIa	5/2 Schedule ≥100 mg/day* (N=18)	3/4 Schedule ≥100 mg/day* (N=75)
# Cycles, mean (SD) [Range]	3.9 (2.62) [0, 10]	1.9 (1.72) [0, 8]
Subjects Exposed to RP-3500 n (%)		
≥1 cycle	17 (94.4%)	57 (76.0%)
≥2 cycles	14 (77.8%)	37 (48.7%)
Interruptions n (%)		
1	8 (44.0%)	16 (21.3%)
2	2 (11.1%)	3 (4.0%)
≥3	5 (27.8%)	2 (2.7%)
Dose Reductions, n (%)		
1	6 (33.3%)	10 (13.3%)
2	3 (16.7%)	1 (1.3%)
Transfusions, n (%)		
Cycle 1	4 (22.2%)	6 (8.0%)
Cycles 1-2	9 (50.0%)	9 (12.0%)
Cycles 1-3	12 (66.7%)	10 (13.2%)



Pharmacokinetic profile RP-3500 exposures meet efficacy targets at ≥100mg

- Half-life is ~ 6 hrs
- Linear Cmax and AUC, consistent across all doses
- Doses ≥100 mg QD achieve predicted efficacious RP-3500 exposures
 - Once daily (QD) regimen selected over twice daily (BID) based on minimal differences in target coverage between these 2 regimens
 - Based on the results of the RP-3500 food effect study, RP-3500 can be given with and without food






RP-3500 Pharmacodynamics

Robust pathway modulation in paired tumor biopsies

Consistent and statistically significant on-treatment increases in DNA damage-induced γ H2AX and p-KAP1 across tumor genotypes (N=21)






Early analysis of treatment duration

Therapy ongoing in 54* (54%) of 101 patients

- Early analysis of therapy duration shows clinical activity across tumor types and STEP2 alterations
- Responses** included:
 - CRPC (ATM, CDK12)
 - Ovarian, post-PARPi (4 BRCA1, 1 RAD51C)
 - ER+ breast (BRCA1)
 - HNSCC (BRCA1)
 - Melanoma (BRCA2)
- Copy number analysis of enrolled gene alterations is ongoing



THERAPEUTICS

Early efficacy observed with RP-3500 ≥100 mg/day


Broad spectrum of efficacy observed

- Meaningful clinical benefit in 34 (49%) of 69 evaluable patients
- Across STEP2 gene alterations
- Across schedules & after PARPi failure
 - 12 responses: 8 RECISTv1.1 cPR/uPR, 2 pts by PCWG3 and 2 pts by GCIG
 (ATM, CDK12, BRCA1, BRCA2, RAD51B, RAD51C and FZR1)
 - **14 patients** ongoing SD \geq 16 weeks

22

- **8 patients** <16w on study: early significant decreases in tumor markers and tumor shrinkage (<30%)
- Late responses also observed: initial RECISTv1.1 partial response (PR) seen at week 16

	5/2 Schedule ≥ 100 mg/day (N=18)	3/4 Schedule ≥ 100 mg/day (N=76)	All patients ≥ 100 mg/day (N=94)
Evaluable pts (≥1 post baseline scan)	17	52	69
Best response	4	8	12
RECISTv1.1	2 cPR*; 1uPR **	2 cPR; 3 uPR [#]	4 cPR; 4uPR
PCWG3 PSA	1	1	2
GCIG CA125	-	2	2
SD (≥16w)	6	8	14
SD (≥6w) ^{&}	6	23	29
PD	6	21	27
Data pending	1	0	1
Discontinued w/o scan	1	3	4
On treatment w/o scan	0	21	21




#1 patient began on PARPi+RP3500 for 2 weeks, before transitioning to RP-3500 monotherapy.
[&] includes the SD>16w patients



Deep molecular responses in TRESR

Circulating tumor DNA (ctDNA) measured serially in 37 pts

- ctDNA, fragmented tumor DNA in circulating blood, may reflect the entire tumor genome as "liquid biopsies" at various time points to monitor tumor during treatment
- Published data suggest that early molecular responses in ctDNA may be correlated with patient benefit during treatment with anticancer drugs
- ctDNA best mean variant allele frequency (mVAF*) measures change in tumor burden
- RP-3500 data show early and significant decrease (>50%) in mVAFR** in tumors with multiple genotypes




*mVAF calculated as % decrease from baseline

**mVAFR is the mean variant allele frequency ratio (relative to baseline). mVAFR capped at +100%



Preliminary analysis suggests ctDNA response may predict clinical benefit


- RP-3500 patients with PRs showed early and frequently significant (>50%) reductions in mVAFR in ctDNA
- Analyses are ongoing to correlate ctDNA responses with clinical efficacy in order to evaluate the predictive power of serial ctDNA measurements



- ctDNA cohort = 37/101 enrolled patients
- mVAFR = mean variant allele frequency ratio as an indirect measure of tumor burden



Ovarian cancer with gBRCA1 mutation



ovarian cancer: Prior platinum, previous failure of PARP inhibitor (best response PD) and docetaxel + avastin (best response PD)

> **REPARE** THERAPEUTICS

(-29.2% ΔP)


CT: SE 2 / IN 104

CT: SE 2 / IN 102


CRPC with CDK12 mutation

Ongoing RECIST cPR

Ongoing PCWG3 PSA response



57 y/o male with CRPC received 6 prior regimens, incl. best response of PD on docetaxel, platinum/etoposide and Ipi/Nivo







CRPC with ATM mutation

Ongoing PCWG3 PSA response

Ongoing RECISTv1.1 uPR, confirmation of response awaited



68 y/o male with CRPC, multiple bone metastases and lymph node disease, with disease progression on 2 prior regimens





Summary – Early Phase 1/2 TRESR trial data

RP-3500 is safe and well tolerated, with mainly G1-2 anemia (only 21.8% G3 overall and 14.5% in chosen schedule)

Likely off-target toxicities, e.g., fatigue or GI events, are infrequent (only up to 3% G3)

RP-3500 RP2D for further monotherapy evaluation is 160mg QD 3d on/4d off

Biomarker data confirm proof-of-mechanism across different tumors with multiple molecular backgrounds

Preliminary antitumor activity observed in patients with cancers harboring selected genomic alterations at doses \geq 100mg

- Meaningful clinical benefit in 34 (49%) of 69 patients
 - **12 patients** with objective tumor responses:
 - 8 RECIST V1.1: cPR/uPR (7 confirmed, 1 unconfirmed)
 - 2 PCWG3 PSA responses
 - 2 GCIG CA125 responses
 - **14 patients** with ongoing RECIST v1.1 SD for at least 16 weeks
 - 8 patients <16 weeks on study: SD with early significant decreases in tumor markers and <30% tumor shrinkage



RP-3500 is in development as a potent, potentially best-in-class, highly selective ATR inhibitor

The TRESR Phase 1/2 study is the largest biomarker-selected trial testing a single agent ATR inhibitor (N=101) and continues to enroll

Early TRESR data provide clinical POC and validate Repare Therapeutics' SNIPRx platform for molecular selection of tumors for ATR inhibitor therapy

Favorable and differentiated safety profile, along with promising and distinct early efficacy, offer a clear direction for further development of RP-3500

Next steps include:

- TRESR Phase 2 expansion cohorts to open imminently
- Combination studies are ongoing or will open shortly



Acknowledgements

The patients and their families who make this trial possible

Participating TRESR Sites for their work and contribution

Billy Hoadley; Christian Brown; Sandra Montez	University of Texas MD Anderson Cancer Center
Emily Gibson; Mary Liebers	Dana Farber Cancer Institute
Danielle McCreary	Sarah Cannon Research Institute/Tennessee Oncology
Alissa Casas, Arousiak Kazarian	Memorial Sloan Kettering Cancer Center
Paula Lee	Duke Cancer Institute
Jocelyn Hubbard	Massachusetts General Hospital
Rachael DiGiulio; Brenton Travers	Rhode Island Hospital/Lifespan
Rachel Wildman	Princess Margaret Cancer Center
Terry Wood; Sinead O'Reilly	The Christie NHS Foundation Trust
Helen Blair	Newcastle Hospital NHS Foundation Trust
Victoria Hall; Victoria Borja Bernal	Sarah Cannon Research Institute UK
Cecilia Sonander Westphal; Emma-Sofie Sønderskov Darre	Righospitalet, Denmark

Precision Oncology Decision Support (PODS) Group at the University of Texas MD Anderson Cancer Center

The Repare Clinical Study Team

Livia Gjylameti, Danielle Ulanet, Parham Nejad, Peter Manley, Marisa Wainszelbaum, Biljana Bazdar-Vinovrski, Stephanie Guerrera, Joseph O'Connell, Victoria Rimkunas, Ian Silverman, Adrian Fretland and Maria Koehler

Treximo (part of the ProPharma Group)

This Study is funded by Repare Therapeutics



RP-3500 next steps







Enrollment to the main component of TRESR Module 1 (RP2D determination) is closed



Recruitment to Module 1 is now closed (goal 120 pts) \bigcirc

Unchanged safety/tolerability profile as of Oct 6th



Update of 4 patients with uPR reported as of AACR-NCI-EORTC 2021 meeting: 3 cPR, 1 uPR



Final results of Module 1 expected to be reported in 2Q 2022 with expected 3-4 months follow up of all M1 patients

Additional Modules in TRESR anticipated to open imminently



Additional details on clinical responders

Tumor type	Genotype	Enrolled Dose Level	Schedule Modifications	Best Response (Aug 15)	Update on uPRs (Oct 6)
Prostate	CDK12	120 QD <u>(5/2)</u>	PR at 6w. Switched to 3/4 after 11w	cPR	
Ovarian	BRCA1	160 QD (3/4)		cPR	
Ovarian	BRCA1	160 QD <u>(5/2)</u>	Switched to 3/4 after 6w	cPR	
Breast	BRCA1	160 QD (3/4)		uPR	Unconfirmed
Prostate	ATM	120 QD <u>(5/2)</u>	Switched to 3/4 after 7w	uPR	Confirmed
Ovarian	BRCA1	120 QD (3/4)*	Switched to monotherapy after 2w	cPR	
Melanoma	BRCA2	120 QD (3/4)		uPR	Confirmed
SCC	BRCA1	160 QD (3/4)		uPR	Confirmed
Prostate	ATM	120 QD <u>(5/2)</u>	Switched to 3/4 after 17w	cPSA**	
Prostate Nonmeasurable disease	ATM	160 QD (3/4)		cPSA	
Ovarian	BRCA1	120 QD (3/4)		cCA-125	
Ovarian	RAD51C	160 QD (3/4)		cCA-125***	

* Initial 32 weeks on talazoparib combination, 23 w on therapy


** Approx. 8 Mo on therapy (SD last scan -26% on Sept 23rd)

REPARE THERAPEUTICS

*** On-Tx 15weeks: SD (-28.7% at last scan on 07Sep)

RP-3500 clinical program as of Oct 6th

Global multicenter study designed for patients with any recurrent tumor with ATM loss or loss of any of the additional 16 STEP² genes



THERAPEUTICS

34

Global multi-center study:

- Phase 2 study with 3 distinct arms designed to deliver PoC
- Expected 4Q 2021 start
- Results will inform discussion with the FDA/EMA on next steps

ATM loss of function

- Selected ATM LoF patients
- Less heavily pre-treated patients than in Module 1

STEP² gene alteration(s)

- Two STEP² genes
- Focused tumor population enriched for these genes


Other STEP² gene alteration(s)

- Selected STEP² genes
- Focused on those un/under-represented in Module 1



RP-3500 updated clinical trial program: additional modules

Trial results to date support expanded clinical development



THERAPEUTICS

RP-3500 key clinical summary

Early TRESR data provide clinical POC and validate Repare Therapeutics' SNIPRx platform

Favorable and differentiated safety profile and distinct early activity, offer a clear direction for further development

RP-3500 RP2D for further monotherapy evaluation is 160mg QD 3d on/4d off

Biomarker data confirm proof-of-mechanism across different tumors with multiple molecular backgrounds

Preliminary results observed in tumors with selected genomic alterations continue to mature


Final efficacy and safety analysis from Module 1 expected in 2Q 22

Meaningful clinical benefit in 34 (49%) of 69 patients as of 15th August:

- **12 patients** with objective tumor responses:
 - 8 RECIST V1.1 cPR/uPR- 1 unconfirmed PR
 - 2 PCWG3 PSA responses
 - 2 GCIG CA125 responses
- **14 patients** with ongoing RECIST v1.1 SD for at least 16 weeks
- 8 patients <16w on study: SD with early significant decreases in tumor markers and <30% tumor shrinkage



Recent progress and upcoming anticipated milestones





Q&A Session

